stockportfolio.pro
Theravance Biopharma, Inc. (TBPH)
Healthcare · Biotechnology · NasdaqGM
Theravance Biopharma, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $48.65M | $15.39M | $60.37M | $73.41M | $71.86M | $55.31M | $51.35M | $57.42M | $64.38M | $107.46M |
| Gross profit | $45.75M | $9.36M | — | — | — | — | — | — | — | — |
| Net income | $-190.67M | $-285.40M | $-215.52M | $-236.46M | $-278.02M | $-199.43M | $872.13M | $-55.19M | $-56.42M | $105.89M |
| Net margin | -391.9% | -1855.0% | -357.0% | -322.1% | -386.9% | -360.6% | 1698.5% | -96.1% | -87.6% | 98.5% |
Source: Theravance Biopharma, Inc. SEC filings (10-K). 14 years of history available in the interactive view.
What growth is priced into TBPH stock?
At today's market cap of $845.47M, Theravance Biopharma, Inc. is priced for free-cash-flow growth of about -17.8% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $238.50M from the FY ending 2025-12-31). For comparison, revenue 8.4%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 14 years of Theravance Biopharma, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track TBPH in your portfolio →
Theravance Biopharma, Inc. financial history by metric
About Theravance Biopharma, Inc.
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
Theravance Biopharma, Inc. — frequently asked questions
What is Theravance Biopharma, Inc.'s revenue?
Theravance Biopharma, Inc. (TBPH) reported revenue of $107.46M for fiscal year 2025, up 66.9% from the prior year, according to its SEC filings.
Is Theravance Biopharma, Inc. profitable?
Yes. TBPH earned net income of $105.89M in fiscal 2025, a net margin of 98.5%.
What is TBPH's P/E ratio?
Theravance Biopharma, Inc. trades at a price-to-earnings ratio of about 7.4 based on the latest data in our nightly-refreshed cache.
How fast is Theravance Biopharma, Inc. growing?
TBPH's revenue grew at roughly 8.4% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Theravance Biopharma, Inc. have?
As of fiscal year 2025, TBPH carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Theravance Biopharma, Inc.'s market cap?
Theravance Biopharma, Inc. (TBPH) has a market capitalization of about $845.47M, based on the latest data in our nightly-refreshed cache.
When does Theravance Biopharma, Inc.'s fiscal year end?
TBPH's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into TBPH stock?
At today's market cap of $845.47M, Theravance Biopharma, Inc. is priced for free-cash-flow growth of about -17.8% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $238.50M from the FY ending 2025-12-31). For comparison, revenue 8.4%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from Theravance Biopharma, Inc.'s official SEC filings (10-K and 10-Q), covering 14 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.